findmyKOL

Robert Figlin, MD

Enriched profile

Interim Director, Cedars-Sinai Cancer; Deputy Director, Samuel Oschin Comprehensive Cancer Institute; Steven Spielberg Family Chair in Hematology-Oncology; Professor of Medicine and Biomedical Sciences · Cedars-Sinai Medical Center

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 Duarte, CA · West · United StatesSpecialtyHematology / OncologyFocusKidney Cancer / RCC+2
Last active 2024findmyKOL type: NationalLatest publicationNone indexedOnline presenceverified 2026Payments2021–2024NIH funding1993–2013Why? →

Robert Figlin is Interim Director, Cedars-Sinai Cancer; Deputy Director, Samuel Oschin Comprehensive Cancer Institute; Steven Spielberg Family Chair in Hematology-Oncology; Professor of Medicine and Biomedical Sciences at Cedars-Sinai Medical Center. ClinicalTrials.gov lists 8 registered studies with this person as an investigator.

Data verified 17 Oct 2026

Overview

Updated 18 Oct 2026

Robert Figlin, MD, is Interim Director, Cedars-Sinai Cancer at Cedars-Sinai Medical Center (Cedars-Sinai Cancer). The public record shows 716 publications with 52,794 citations (h-index 107), centered on Kidney Cancer / RCC, Lung Cancer (NSCLC/SCLC), Kidney Neoplasms. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 11 companies, 6 NIH-funded awards (1993–2013).

  • Top research focus: Kidney Cancer / RCC
  • 8 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 11 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Kidney Cancer / RCC3 trialsLung Cancer (NSCLC/SCLC)3 trialsKidney Neoplasms2 trials

Research focus

OpenAlex concept fingerprint
Kidney Cancer / RCCLung Cancer (NSCLC/SCLC)Kidney Neoplasms

Drugs & molecules

across trials, industry payments and publications
Cabometyxgeneric · CabozantinibClinical trials—Industry payments3Publications—Inlytageneric · AxitinibClinical trials—Industry payments3Publications—Fotivdageneric · TivozanibClinical trials—Industry payments2Publications—Lenvimageneric · LenvatinibClinical trials—Industry payments2Publications—Amtagvigeneric · LifileucelClinical trials—Industry payments1Publications—Welireggeneric · BelzutifanClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
4DMedical USA IncClinical trials—Industry payments26Jonsson Comprehensive Cancer CenterClinical trials5Industry payments—Exelixis Inc.Clinical trials—Industry payments3Janssen Research & Development, LLCClinical trials—Industry payments3Kyowa Kirin, Inc.Clinical trials—Industry payments3Pfizer Inc.Clinical trials—Industry payments3AVEO Pharmaceuticals, Inc.Clinical trials—Industry payments2Eisai Inc.Clinical trials—Industry payments2Argos TherapeuticsClinical trials1Industry payments—BioMedicinesClinical trials1Industry payments—E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments1Iovance Biotherapeutics, Inc.Clinical trials—Industry payments1Merck Sharp & Dohme CorporationClinical trials—Industry payments1Merck Sharp & Dohme LLCClinical trials—Industry payments1RibozyomeClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
107h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
8clinical trials

Investigator role on registered studies.

View trials ↓
11companies · 2021–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
6NIH grants · 1993–2013

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:

All 8 trial records: search, sort and filter.Explore →

Industry payments

Updated 18 Oct 2026

11 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:

All 16 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Kinase inhibitor83.1%
    Lenvima41%Cabometyx33%Everolimus26%
    Part D<11 patients
    Hypoxia-inducible Factor Inhibitor16.9%
    Welireg100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 18 Oct 2026

6 NIH research awards on record, funded 1993–2013 per NIH RePORTER. The latest:

All 47 award records: search, sort and filter.Explore →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Online presence

Updated 18 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/robert-figlin-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/robert-figlin-3b1072148

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/profile/Robert-Figlin

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • LinkedIn

    linkedin.com/in/robert-figlin-07b57427

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • X / Twitter

    x.com/ASCO/status/1944849562931282216

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
  • X / Twitter

    x.com/cedarssinai/status/475019383849627648

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Medical College of Pennsylvania (1976); internal medicine residency and chief residency, Cedars-Sinai Medical Center; hematology-oncology fellowship, UCLA David Geffen School of Medicine

    1976
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
  • MD
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cedars-sinai.org ↗

Editorial & leadership roles

journal and society appointments
  • Honorary Editor

    Kidney Cancer Journal

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidney-cancer-journal.com ↗
  • Fellow

    American College of Physicians (FACP)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →accc-cancer.org ↗

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.